9478 related articles for article (PubMed ID: 14651224)
1. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS
Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
[TBL] [Abstract][Full Text] [Related]
2. Pentostatin (2prime prime or minute-Deoxycoformycin): Clinical Pharmacology, Role In Cancer Chemotherapy, and Future Prospects.
Spiers AS
Am J Ther; 1995 Mar; 2(3):196-216. PubMed ID: 11847552
[TBL] [Abstract][Full Text] [Related]
3. Phase II trials of pentostatin (Nipent) in hairy cell leukemia.
Kraut EH
Semin Oncol; 2000 Apr; 27(2 Suppl 5):27-31. PubMed ID: 10877048
[TBL] [Abstract][Full Text] [Related]
4. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
Foss FM
Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin for the treatment of indolent lymphoproliferative disorders.
Ho AD; Hensel M
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S2-10. PubMed ID: 16549110
[TBL] [Abstract][Full Text] [Related]
6. Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
Ho AD; Thaler J; Willemze R; Lauria F; Derossi G; Kuse R; Stryckmans P; Blanc CM; Cataldo F; McVie G
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():60-2. PubMed ID: 2653520
[TBL] [Abstract][Full Text] [Related]
7. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Dearden CE; Matutes E; Catovsky D
Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
[TBL] [Abstract][Full Text] [Related]
8. Pentostatin in chronic lymphocytic leukemia.
Sauter C; Lamanna N; Weiss MA
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115
[TBL] [Abstract][Full Text] [Related]
9. New purine analogues for the treatment of chronic B-cell malignancies.
Gribbin TE
Henry Ford Hosp Med J; 1991; 39(2):98-102. PubMed ID: 1679757
[TBL] [Abstract][Full Text] [Related]
10. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
11. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
[TBL] [Abstract][Full Text] [Related]
12. Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia.
Dillman RO
Expert Rev Anticancer Ther; 2004 Feb; 4(1):27-36. PubMed ID: 14748654
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on purine analogues.
Cheson BD
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S109-16. PubMed ID: 9137964
[TBL] [Abstract][Full Text] [Related]
14. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
Fabianowska-Majewska K; Wyczechowska D
Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
[TBL] [Abstract][Full Text] [Related]
15. New antimetabolites in the treatment of human malignancies.
Cheson BD
Semin Oncol; 1992 Dec; 19(6):695-706. PubMed ID: 1361080
[TBL] [Abstract][Full Text] [Related]
16. Pentostatin and purine analogs for indolent lymphoid malignancies.
Ho AD; Hensel M
Future Oncol; 2006 Apr; 2(2):169-83. PubMed ID: 16563086
[TBL] [Abstract][Full Text] [Related]
17. Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse.
Ho DH; Pincus C; Carter CJ; Benjamin RS; Freireich EJ; Bodey GP
Cancer Treat Rep; 1980; 64(4-5):629-33. PubMed ID: 6968622
[TBL] [Abstract][Full Text] [Related]
18. Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia.
O'Dwyer PJ; Cheson BD; Leyland-Jones B; King SA; Hoth DF
Oncology (Williston Park); 1988 Jun; 2(6):17-23, 26-7. PubMed ID: 3079330
[TBL] [Abstract][Full Text] [Related]
19. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
20. CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).
Sato K; Dang NH
Int J Oncol; 2003 Mar; 22(3):481-97. PubMed ID: 12579300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
